April 19, 2024

Asthma Therapeutics Market Size to Hit USD 45.28 Bn by 2033

The asthma therapeutics market size is poised to grow by USD 45.28 billion by 2033 from USD 26.84 billion in 2023, exhibiting a CAGR of 5.37% during the forecast period 2024-2033.

Key Points

  • North America dominated the market with the largest market share of 51% in 2023.
  • Asia Pacific is observed to witness the fastest rate of growth during the forecast period.
  • By drug class, the anti-inflammatory segment has contributed the largest market share of 63% in 2023.
  • By drug class, the combination therapy segment is observed to witness a notable rate of growth during the forecast period.
  • By product, the inhalers segment dominated the market in 2023.
  • By route of administration, the inhaled segment recorded more than 47% of revenue share in 2023.

Asthma Therapeutics Market Size 2024 to 2033

Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Asthma therapeutics market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.

To begin with, the Asthma therapeutics Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.

Get a Sample Report: https://www.precedenceresearch.com/sample/3875

Asthma Therapeutics Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 5.37%
Global Market Size in 2023 USD 26.84 Billion
Global Market Size by 2033 USD 45.28 Billion
U.S. Market Size in 2023 USD 9.58 Billion
U.S. Market Size by 2033 USD 16.16 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Drug Class, By Product, and By Route of Administration
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: UV LED Market Size to Reach USD 4,436.57 Million by 2033

The empirical study on the global Asthma therapeutics market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Asthma therapeutics Market. Our market report for the Asthma therapeutics market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi.
  • Koninklijke Philips N.V.
  • BD
  • Covis Pha

Data Sources and Methodology

To gather comprehensive insights on the Global Asthma therapeutics Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Asthma therapeutics Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Asthma therapeutics market report exclusively from precedence research

  • The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2024 to 2033.

Key Features of the Report:

  • Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
  • Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
  • Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Drug Class

  • Anti- inflammatory
  • Bronchodilators
  • Combination Therapy

By Product

  • Inhalers
    • Dry Powder
    • Metered Dose
    • Soft Mist
  • Nebulizers

By Route of Administration

  • Oral
  • Inhaled
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Reasons to Consider Purchasing the Report:

  • Enhance your market research capabilities by accessing this comprehensive and precise report on the global Asthma therapeutics market.
  • Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
  • Benefit from in-depth research and analysis of the latest trends shaping the global Asthma therapeutics market.
  • Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Asthma therapeutics market.
  • Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
  • Discover not only the cutting-edge technological advancements in the global Asthma therapeutics market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Asthma Therapeutics Market 

5.1. COVID-19 Landscape: Asthma Therapeutics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Asthma Therapeutics Market, By Drug Class

8.1. Asthma Therapeutics Market, by Drug Class, 2024-2033

8.1.1 Anti- inflammatory

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Bronchodilators

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Combination Therapy

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Asthma Therapeutics Market, By Product

9.1. Asthma Therapeutics Market, by Product, 2024-2033

9.1.1. Inhalers

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Nebulizers

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Asthma Therapeutics Market, By Route of Administration 

10.1. Asthma Therapeutics Market, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Inhaled

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Asthma Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.2. Market Revenue and Forecast, by Product (2021-2033)

11.1.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical Industries Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GSK plc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co., Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. F. Hoffmann-La Roche Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AstraZeneca

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Boehringer Ingelheim International GmbH

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Sanofi

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Koninklijke Philips N.V.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. BD

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Covis Pha

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

 

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

Precedence Statistics – Empowering Your Data Insights

 

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *